10/26/09 President Obama Declares National Emergency

CNN Reports President Obama Declares National Emergency To Deal

With The "Rapid Increase In Illness" From The H1N1 Influenza Virus;

Cannabis Science Continues Progress On Its Research To Show Cannabis

Can Reduce Risk of Death from "Swine Flu"

COLORADO SPRINGS, Colo.--(BUSINESS WIRE)--Cannabis Science Inc. (NASD OTCBB: CBIS) an emerging pharmaceutical

cannabis company, is urging that US government recognize that

phytocannabinoid pharmaceutical products can help reduce Adult

Respiratory Distress Syndrome (ARDS)-associated deaths from both the

Avian and Swine Influenza infections, as President Obama declares a

national emergency. President Obama signed the declaration late Friday

and announced it Saturday. We urge readers go to: http://www.cnn.com/2009/HEALTH/10/24/h1n1.obama/index.html

to read the whole story on the CNN website.

President Obama stated, "The 2009 H1N1 pandemic continues to evolve. The

rates of illness continue to rise rapidly within many communities across

the nation, and the potential exists for the pandemic to overburden

health care resources in some localities."

President Obama continued with, "Thus, in recognition of the continuing

progression of the pandemic, and in further preparation as a nation, we

are taking additional steps to facilitate our response."

Cannabis Science, Inc. President & CEO Dr. Robert Melamede stated,

“Clearly, there is little time to gear up the mass production of

pharmaceutical cannabis products to meet the immediate needs of this

national emergency. However, President Obama’s new policy of federal

tolerance of medical marijuana where is it legal under state laws, makes

it possible for Cannabis Science to work with the medical marijuana

patients and providers in some states to help develop products to meet

patients’ needs. If the situation is dire enough to justify calling it a

“National Emergency”, then surely medical ethics require that we work

diligently with all relevant research.”

Dr. Melamede also deplored efforts in Los Angeles and other areas to

close dispensaries and/or ban edibles. “It is hard to imagine a more

wrong-headed approach or a worse time to deprive people of access to

cannabis edibles. Again, we recommend, based on sound scientific

principles, that medical marijuana users should switch to edibles if

they come down with an influenza infection. We believe that the

irritation associated with the pulmonary route, when a person has an

influenza infection, may lead to unnecessary deaths. In contrast, oral

administration may prevent many deaths. We hope that due to the

magnitude of this pandemic threat, that the FDA will fast track our

proposal."

Please visit our website http://www.cannabisscience.com

in the next few days as we will be posting a survey for those who

encountered the H1N1 and other influenza symptoms and experiences. This

Cannabis Science Survey will be designed to acquire anecdotal human data

regarding the effects of Medical Marijuana on influenza infections. The

company plans to monitor activity, collect data, and report findings in

its reports to the FDA.

Cannabis Science H1N1 Swine Flu Formulation:

Dr. Melamede explains, “We now know that the endocannabinoid system

plays a critical role in maintaining human health. The human body

produces Endocannabinoids on demand when they are needed. They help

restore homeostasis (biochemical balance). The Cannabis plant produces

Phytocannabinoids. When the human body has endocannabinoid deficiencies,

it cannot effectively restore the healthy biochemical state needed to

counter a particular illness. Phytocannabinoids from the Cannabis plant

can replace the deficient endocannabinoid activity in the human body to

restore a health-promoting level of cannabinoid activity. Cannabis

Science will test its pharmaceutical products with FDA guidance and

oversight to determine if it will reduce ARDS-associated deaths from

both the Avian and Swine influenza infections.”

This Press Release includes forward-looking statements within the

meaning of Section 27A of the Securities Act of 1933 and Section 21E of

the Securities Act of 1934. A statement containing works such as

"anticipate," "seek," intend," "believe," "plan," "estimate," "expect,"

"project," "plan," or similar phrases may be deemed "forward-looking

statements" within the meaning of the Private Securities Litigation

Reform Act of 1995. Some or all of the events or results anticipated by

these forward-looking statements may not occur. Factors that could cause

or contribute to such differences include the future U.S. and global

economies, the impact of competition, and the Company's reliance on

existing regulations regarding the use and development of cannabis-based

drugs. Cannabis Science, Inc. does not undertake any duty nor does it

intend to update the results of these forward-looking statements.

Contact:

Cannabis Science Inc.

Dr. Robert J. Melamede, 888-889-0888

President & CEO

\n info@cannabisscience.com

This e-mail address is being protected from spambots. You need JavaScript enabled to view it

http://www.cannabisscience.com

or

Peter Glaser, 954-687-3717

Investor Relations

\n info@cannabisscience.com

This e-mail address is being protected from spambots. You need JavaScript enabled to view it

http://www.cannabisscience.com


Industry News